Gland Pharma Limited
Symbol: GLAND.NS
NSE
1708.85
INRMarket price today
42.9265
P/E Ratio
1.6233
PEG Ratio
281.47B
MRK Cap
- 0.00%
DIV Yield
Gland Pharma Limited (GLAND-NS) Financial Statements
Balance Sheet
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 119605.7 | 38362 | 32427.2 | 24465 | |||||||
balance-sheet.row.short-term-investments | 154862.64 | 19273 | 29268.9 | 19546.8 | |||||||
balance-sheet.row.net-receivables | 22690.46 | 8715.3 | 12514.7 | 12726.8 | |||||||
balance-sheet.row.inventory | 40296.48 | 19453 | 11856.7 | 12751.7 | |||||||
balance-sheet.row.other-current-assets | 5282.69 | 2477.8 | 1722.3 | 1292.9 | |||||||
balance-sheet.row.total-current-assets | 187875.33 | 69008.1 | 58520.8 | 51236.4 | |||||||
balance-sheet.row.property-plant-equipment-net | 51493.3 | 17361 | 17269 | 13244.4 | |||||||
balance-sheet.row.goodwill | 4555.95 | 0 | 0 | 0 | |||||||
balance-sheet.row.intangible-assets | 1656.81 | 116.6 | 125.3 | 0 | |||||||
balance-sheet.row.goodwill-and-intangible-assets | 6212.76 | 116.6 | 125.3 | 0 | |||||||
balance-sheet.row.long-term-investments | -16835.11 | -733.7 | 2000 | -19477.3 | |||||||
balance-sheet.row.tax-assets | 1402.64 | 958.9 | -415.1 | 0 | |||||||
balance-sheet.row.other-non-current-assets | -39445.19 | 1064.4 | 836.1 | 19957.3 | |||||||
balance-sheet.row.total-non-current-assets | 2828.4 | 18767.3 | 19815.4 | 13724.4 | |||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-assets | 190703.73 | 87775.4 | 78336.2 | 64960.8 | |||||||
balance-sheet.row.account-payables | 15655.98 | 5873.5 | 4628.5 | 4007.3 | |||||||
balance-sheet.row.short-term-debt | 2102.99 | 7.1 | 2.6 | 3 | |||||||
balance-sheet.row.tax-payables | 624.79 | 9.8 | 179.8 | 286.9 | |||||||
balance-sheet.row.long-term-debt-total | 1511.84 | 37.4 | 44.8 | 47 | |||||||
Deferred Revenue Non Current | 1298.89 | 49.9 | 55.5 | 56.7 | |||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 2180.49 | - | - | - | |||||||
balance-sheet.row.other-current-liab | 3290.63 | 924.7 | 552.6 | 63.3 | |||||||
balance-sheet.row.total-non-current-liabilities | 5396.07 | 896.8 | 939.8 | 803.1 | |||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.capital-lease-obligations | 449.53 | 6.3 | 8.1 | 9.3 | |||||||
balance-sheet.row.total-liab | 28049.42 | 8188.1 | 6760 | 5928.4 | |||||||
balance-sheet.row.preferred-stock | 15.59 | 15.6 | 0 | 0 | |||||||
balance-sheet.row.common-stock | 329.4 | 164.7 | 164.3 | 163.6 | |||||||
balance-sheet.row.retained-earnings | 60153.88 | 60153.9 | 52343.4 | 40226.8 | |||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 245541.11 | -15.6 | 114.5 | 240.9 | |||||||
balance-sheet.row.other-total-stockholders-equity | 19268.64 | 19268.6 | 18953.9 | 18401.1 | |||||||
balance-sheet.row.total-stockholders-equity | 325308.62 | 79587.2 | 71576.2 | 59032.4 | |||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 353358.04 | 87775.4 | 78336.2 | 64960.8 | |||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-equity | 325308.62 | 79587.2 | 71576.2 | 59032.4 | |||||||
balance-sheet.row.total-liabilities-and-total-equity | 353358.04 | - | - | - | |||||||
Total Investments | 138027.53 | 18539.3 | 2000 | 69.5 | |||||||
balance-sheet.row.total-debt | 3614.83 | 44.5 | 47.4 | 50 | |||||||
balance-sheet.row.net-debt | 38871.77 | -19044.4 | -3110.8 | -4868.3 |
Cash Flow Statement
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 6587.23 | 10545.8 | 16185.5 | 13348.1 | |||||||
cash-flows.row.depreciation-and-amortization | 2894.99 | 1467.4 | 1103 | 987.8 | |||||||
cash-flows.row.deferred-income-tax | 0 | 0 | -4143.8 | -3254 | |||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 46.2 | 155.3 | |||||||
cash-flows.row.change-in-working-capital | 0 | -4179.4 | -3930.8 | -4357.6 | |||||||
cash-flows.row.account-receivables | 0 | 1440 | -4195.7 | -602 | |||||||
cash-flows.row.inventory | 0 | -7596.3 | 895 | -5188.9 | |||||||
cash-flows.row.account-payables | 0 | 1209.8 | 658.5 | 1428.2 | |||||||
cash-flows.row.other-working-capital | 0 | 767.2 | -1288.6 | 5.1 | |||||||
cash-flows.row.other-non-cash-items | -6587.23 | -4194.1 | -1352.4 | -830.4 | |||||||
cash-flows.row.net-cash-provided-by-operating-activities | 5789.98 | 0 | 0 | 0 | |||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -2231.2 | -5221.2 | -2287.8 | |||||||
cash-flows.row.acquisitions-net | 0 | -12705.6 | 6117.2 | 4.3 | |||||||
cash-flows.row.purchases-of-investments | 0 | -4699.8 | -16818.1 | -13575.9 | |||||||
cash-flows.row.sales-maturities-of-investments | 0 | 17405.4 | 10700.9 | -4.3 | |||||||
cash-flows.row.other-investing-activites | 0 | 14313.1 | -4805 | 623.7 | |||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 12081.9 | -10026.2 | -15240 | |||||||
cash-flows.row.debt-repayment | 0 | -1.1 | -1.4 | -8.9 | |||||||
cash-flows.row.common-stock-issued | 0 | 215 | 385.5 | 12418.1 | |||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.other-financing-activites | 0 | -64.7 | -35.2 | -24.6 | |||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 149.2 | 349 | 12384.6 | |||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 30 | 33.1 | 35.8 | |||||||
cash-flows.row.net-change-in-cash | 5789.98 | 15900.8 | -1736.4 | 3229.7 | |||||||
cash-flows.row.cash-at-end-of-period | 51207.44 | 19089 | 3188.2 | 4924.6 | |||||||
cash-flows.row.cash-at-beginning-of-period | 45417.46 | 3188.2 | 4924.6 | 1695 | |||||||
cash-flows.row.operating-cash-flow | 5789.98 | 3639.7 | 7907.7 | 6049.3 | |||||||
cash-flows.row.capital-expenditure | 0 | -2231.2 | -5221.2 | -2287.8 | |||||||
cash-flows.row.free-cash-flow | 5789.98 | 1408.5 | 2686.5 | 3761.5 |
Income Statement Row
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 49122.83 | 36246 | 43841.4 | 34236.4 | |||||||
income-statement-row.row.cost-of-revenue | 19385.47 | 16854.3 | 21092.2 | 14918.7 | |||||||
income-statement-row.row.gross-profit | 29737.36 | 19391.7 | 22749.3 | 19317.6 | |||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||
income-statement-row.row.research-development | 2016 | - | - | - | |||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.other-expenses | 1670.27 | 2404.6 | 16 | 82.8 | |||||||
income-statement-row.row.operating-expenses | 21203.94 | 10611.5 | 8745.5 | 7280.4 | |||||||
income-statement-row.row.cost-and-expenses | 40589.41 | 27465.7 | 29837.7 | 22199.2 | |||||||
income-statement-row.row.interest-income | 1783.74 | 1794.2 | 1386.5 | 859.5 | |||||||
income-statement-row.row.interest-expense | 184.45 | 74.5 | 34 | 29.1 | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.total-other-income-expensenet | 190.97 | 1701.4 | 2185.2 | 1313.7 | |||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||
income-statement-row.row.other-operating-expenses | 1670.27 | 2404.6 | 16 | 82.8 | |||||||
income-statement-row.row.total-operating-expenses | 190.97 | 1701.4 | 2185.2 | 1313.7 | |||||||
income-statement-row.row.interest-expense | 184.45 | 74.5 | 34 | 29.1 | |||||||
income-statement-row.row.depreciation-and-amortization | 2894.99 | 1467.4 | 1103 | 987.8 | |||||||
income-statement-row.row.ebitda-caps | 12534.07 | - | - | - | |||||||
income-statement-row.row.operating-income | 9263.66 | 8844.4 | 14000.3 | 12034.5 | |||||||
income-statement-row.row.income-before-tax | 9454.63 | 10545.8 | 16185.5 | 13348.1 | |||||||
income-statement-row.row.income-tax-expense | 2867.4 | 2735.4 | 4068.9 | 3378.5 | |||||||
income-statement-row.row.net-income | 6587.23 | 7810.4 | 12116.6 | 9969.6 |
Frequently Asked Question
What is Gland Pharma Limited (GLAND.NS) total assets?
Gland Pharma Limited (GLAND.NS) total assets is 87775350000.000.
What is enterprise annual revenue?
The annual revenue is 29185790000.000.
What is firm profit margin?
Firm profit margin is 0.605.
What is company free cash flow?
The free cash flow is 35.155.
What is enterprise net profit margin?
The net profit margin is 0.134.
What is firm total revenue?
The total revenue is 0.189.
What is Gland Pharma Limited (GLAND.NS) net profit (net income)?
The net profit (net income) is 7810430000.000.
What is firm total debt?
The total debt is 44530000.000.
What is operating expences number?
The operating expences are 10611470000.000.
What is company cash figure?
Enretprise cash is -21447340000.000.